Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration

Neurodegener Dis Manag. 2015 Aug;5(4):345-64. doi: 10.2217/nmt.15.19. Epub 2015 Aug 21.

Abstract

Mitochondrial impairment and metal dyshomeostasis are suggested to be associated with many neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and Friedreich's ataxia. Treatments aimed at restoring metal homeostasis are highly effective in models of these diseases, and clinical trials hold promise. However, in general, the effect of these treatments on mitochondrial metal homeostasis is unclear, and the contribution of mitochondrial metal dyshomeostasis to disease pathogenesis requires further investigation. This review describes the role of metals in mitochondria in health, how mitochondrial metals are disrupted in neurodegenerative diseases, and potential therapeutics aimed at restoring mitochondrial metal homeostasis and function.

Keywords: Alzheimer's disease; Cu-ATSM; Friedreich's ataxia; Huntington's disease; Parkinson's disease; amyotrophic lateral sclerosis; chelating agents; deferiprone; mitochondria; superoxide dismutase.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Brain / metabolism*
  • Brain Chemistry*
  • Clinical Trials as Topic
  • Homeostasis*
  • Humans
  • Iron / metabolism
  • Metalloproteins / metabolism*
  • Mitochondrial Diseases / metabolism*
  • Neurodegenerative Diseases / metabolism*
  • Neurodegenerative Diseases / therapy*
  • Oxyquinoline / metabolism
  • Superoxide Dismutase / metabolism
  • Superoxide Dismutase-1

Substances

  • Metalloproteins
  • SOD1 protein, human
  • Oxyquinoline
  • Iron
  • Superoxide Dismutase
  • Superoxide Dismutase-1